Mutations in the epidermal growth factor receptor (EGFR) gene are predictive of the response to EGFR tyrosine kinase inhibitors (TKIs). The ViennaLab assays identify thirty EGFR mutations relevant for non-small cell lung cancer (NSCLC) TKI therapy.

EGFR & EGFR T790M

• NSCLC comprises approximately 85% of all lung cancers. Tumor specimens from patients should be tested for the presence of EGFR mutations prior to TKI treatment.
• Patients carrying EGFR mutations known as `activating mutations´ may benefit from first- or second- or third-generation TKIs. Patients carrying the `resistance mutation´ EGFR T790M may benefit from the third-generation TKI osimertinib.
• The EGFR XL StripAssay^® and EGFR T790M RealFast™ Assay are designed to assist clinicians in the stratification of patients considered for TKI therapy.